Cancer

RNAi oncology research collaboration announced

Published in Cancer Weekly, February 24th, 2004

Sirna Therapeutics, Inc., (RNAI) announced an 18-month collaboration with Eli Lilly & Company (LLY) in which Lilly and Sirna will jointly investigate Sirna's proprietary modified small interfering RNAs (siRNAs) against specific oncology targets provided by Lilly.

Financial terms were not disclosed.

"This collaboration represents a significant step forward in Sirna's development of RNAi-based therapeutics and is our first alliance with a major pharmaceutical company," said Howard W. Robin, president and chief executive officer of Sirna Therapeutics.

"We chose Lilly as a partner based on Lilly's extensive expertise in developing...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-02-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry